

CURRICULUM VITAE

Date of Revision: May 21, 2021
Name: Jean-Dominique Gallezot, PhD
School: Yale School of Medicine

Education:

PhD, Universite Pierre et Marie Curie, Paris, France 2006

Career/Academic Appointments:

2006 - 2008 Postdoctoral Associate, Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT
2008 - 2020 Associate Research Scientist, Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT
2020 - present Research Scientist, Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT

Grants/Clinical Trials History:

Current Grants

Agency: NIH/NIBIB
I.D.#: R21EB026759
Title: Non-invasive Estimation of the Arterial Input Function in PET Studies using Whole-Body Physiological Models
P.I.: Gallezot, Jean-Dominique
Role: PD/PI
Percent effort: N/A
Direct costs per year: \$133,000.00
Total costs for project period: \$670,000.00
Project period: 10/1/2019 - 6/30/2022

Current Clinical Trials

Agency: The University of Texas Health Science Center at Houston
I.D.#: HIC# 1312013188
Title: Cognitive control and cocaine dependence: thalamic noradrenergic processes
P.I.: Chiang-Shan Ray Li
Role: Sub-Investigator
Percent effort: N/A
Total costs for project

period: N/A
Project period: 4/17/2014

Agency: NO FUNDING
I.D.#: HIC# 1202009726
Title: PET and MRI Imaging in Multiple Sclerosis Patients
P.I.: Ming-Kai Chen
Role: Sub-Investigator
Percent effort: N/A
Total costs for project
period: N/A
Project period: 3/30/2012

Past Clinical Trials

Agency: National Institute of Mental Health (NIMH)
I.D.#: HIC# 1409014551
Title: PET Imaging of Microglia with [11C]PBR28 in Young Adults at High and Low Risk for Thought Disorders
P.I.: Tyrone Cannon
Role: Sub-Investigator
Percent effort: N/A
Total costs for project
period: N/A
Project period: 9/23/2015 - 9/4/2019

Agency: Yale University School of Medicine
I.D.#: HIC# 1107008743
Title: High Resolution Imaging and Spectroscopy at 3T and 7T in Multiple Sclerosis
P.I.: Christoph Juchem
Role: Sub-Investigator
Percent effort: N/A
Total costs for project
period: N/A
Project period: 7/27/2011 - 7/27/2017

Agency: EMD Serono, Inc.
I.D.#: HIC# 1401013272
Title: Allocentric Memory as a Novel Measure of Cognitive Inefficiency: Sensitivity in Multiple Sclerosis (MS) Subjects and Relationship With Resting State Functional MRI
P.I.: Franklin Brown
Role: Sub-Investigator
Percent effort: N/A
Total costs for project

period: N/A
Project period: 1/29/2014 - 1/30/2017

Pending Clinical Trials

Agency: National Institutes of Health (NIH)
I.D.#: HIC# 2000026389EXEMPT
Title: Non-invasive Estimation of the Arterial Input Function in PET Studies using Whole-Body Physiological Models
Role: Principal Investigator
Percent effort: N/A
Total costs for project
period: N/A
Project period: 8/26/2019

Bibliography:

Peer-Reviewed Original Research

1. **Gallezot JD**, Bottlaender M, Grégoire MC, Roumenov D, Deverre JR, Coulon C, Ottaviani M, Dollé F, Syrota A, Valette H. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2005, 46:240-7.
2. **Gallezot JD**, Bottlaender MA, Delforge J, Valette H, Saba W, Dollé F, Coulon CM, Ottaviani MP, Hinnen F, Syrota A, Grégoire MC. Quantification of cerebral nicotinic acetylcholine receptors by PET using 2-[18F]fluoro-A-85380 and the multiinjection approach. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2008, 28:172-89.
3. Kas A, Bottlaender M, **Gallezot JD**, Vidailhet M, Villafane G, Grégoire MC, Coulon C, Valette H, Dollé F, Ribeiro MJ, Hantraye P, Remy P. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2009, 29:1601-8.
4. Jin X, Mulnix T, Planeta-Wilson B, **Gallezot JD**, Carson RE. Accuracy of Head Motion Compensation for the HRRT: Comparison of Methods. *IEEE Nuclear Science Symposium Conference Record. Nuclear Science Symposium* 2009, 2009:3199-3202.
5. Yan J, Planeta-Wilson B, **Gallezot JD**, Carson RE. Initial Evaluation of Direct 4D Parametric Reconstruction with Human PET Data. *IEEE Nuclear Science Symposium Conference Record. Nuclear Science Symposium* 2009, 2009:2503-2506.
6. Ding YS, Singhal T, Planeta-Wilson B, **Gallezot JD**, Nabulsi N, Labaree D, Ropchan J, Henry S, Williams W, Carson RE, Neumeister A, Malison RT. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT. *Synapse (New York, N.Y.)* 2010, 64:30-8.
7. **Gallezot JD**, Nabulsi N, Neumeister A, Planeta-Wilson B, Williams WA, Singhal T, Kim S, Maguire RP, McCarthy T, Frost JJ, Huang Y, Ding YS, Carson RE. Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. *Journal Of Cerebral Blood Flow And Metabolism :*

- Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism 2010, 30:196-210.
8. Hu J, Henry S, **Gallezot JD**, Ropchan J, Neumaier JF, Potenza MN, Sinha R, Krystal JH, Huang Y, Ding YS, Carson RE, Neumeister A. Serotonin 1B receptor imaging in alcohol dependence. *Biological Psychiatry* 2010, 67:800-3.
 9. Hannestad J, **Gallezot JD**, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. *Biological Psychiatry* 2010, 68:854-60.
 10. Murrough JW, Huang Y, Hu J, Henry S, Williams W, **Gallezot JD**, Bailey CR, Krystal JH, Carson RE, Neumeister A. Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. *Biological Psychiatry* 2011, 70:1033-8.
 11. **Gallezot JD**, Weinzimmer D, Nabulsi N, Lin SF, Fowles K, Sandiego C, McCarthy TJ, Maguire RP, Carson RE, Ding YS. Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. *NeuroImage* 2011, 56:268-79.
 12. Murrough JW, Czermak C, Henry S, Nabulsi N, **Gallezot JD**, Gueorguieva R, Planeta-Wilson B, Krystal JH, Neumaier JF, Huang Y, Ding YS, Carson RE, Neumeister A. The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. *Archives Of General Psychiatry* 2011, 68:892-900.
 13. Murrough JW, Henry S, Hu J, **Gallezot JD**, Planeta-Wilson B, Neumaier JF, Neumeister A. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. *Psychopharmacology* 2011, 213:547-53.
 14. Lin SF, Fan X, Yeckel CW, Weinzimmer D, Mulnix T, **Gallezot JD**, Carson RE, Sherwin RS, Ding YS. Ex vivo and in vivo evaluation of the norepinephrine transporter ligand [11C]MRB for brown adipose tissue imaging. *Nuclear Medicine And Biology* 2012, 39:1081-6.
 15. Hannestad J, **Gallezot JD**, Schafbauer T, Lim K, Kloczynski T, Morris ED, Carson RE, Ding YS, Cosgrove KP. Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. *NeuroImage* 2012, 63:232-9.
 16. Matuskey D, Pittman B, Planeta-Wilson B, Walderhaug E, Henry S, **Gallezot JD**, Nabulsi N, Ding YS, Bhagwagar Z, Malison R, Carson RE, Neumeister A. Age effects on serotonin receptor 1B as assessed by PET. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2012, 53:1411-4.
 17. **Gallezot JD**, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, Huang Y, Laruelle M, Carson RE, Rabiner EA. Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. *Synapse (New York, N.Y.)* 2012, 66:489-500.
 18. Hannestad J, DellaGioia N, **Gallezot JD**, Lim K, Nabulsi N, Esterlis I, Pittman B, Lee JY, O'Connor KC, Pelletier D, Carson RE. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. *Brain, Behavior, And Immunity* 2013, 33:131-8.
 19. Naganawa M, Nabulsi N, Planeta B, **Gallezot JD**, Lin SF, Najafzadeh S, Williams W, Ropchan J, Labaree D, Neumeister A, Huang Y, Carson RE. Tracer kinetic modeling of [(11)C]AFM, a new PET imaging agent for the serotonin transporter. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2013, 33:1886-96.

20. Jin X, Mulnix T, **Gallezot JD**, Carson RE. Evaluation of motion correction methods in human brain PET imaging--a simulation study based on human motion data. *Medical Physics* 2013, 40:102503.
21. Pietrzak RH, **Gallezot JD**, Ding YS, Henry S, Potenza MN, Southwick SM, Krystal JH, Carson RE, Neumeister A. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. *JAMA Psychiatry* 2013, 70:1199-1205.
22. Lee DE, **Gallezot JD**, Zheng MQ, Lim K, Ding YS, Huang Y, Carson RE, Morris ED, Cosgrove KP. Test-retest reproducibility of [¹¹C]-(+)-propyl-hexahydro-naphtho-oxazin positron emission tomography using the bolus plus constant infusion paradigm. *Molecular Imaging* 2013, 12:77-82.
23. Potenza MN, Walderhaug E, Henry S, **Gallezot JD**, Planeta-Wilson B, Ropchan J, Neumeister A. Serotonin 1B receptor imaging in pathological gambling. *The World Journal Of Biological Psychiatry : The Official Journal Of The World Federation Of Societies Of Biological Psychiatry* 2013, 14:139-45.
24. Ding YS, Naganawa M, **Gallezot JD**, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. *NeuroImage* 2014, 86:164-71.
25. Li CS, Potenza MN, Lee DE, Planeta B, **Gallezot JD**, Labaree D, Henry S, Nabulsi N, Sinha R, Ding YS, Carson RE, Neumeister A. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(¹¹C)O-methylreboxetine. *NeuroImage* 2014, 86:306-10.
26. Matuskey D, Bhagwagar Z, Planeta B, Pittman B, **Gallezot JD**, Chen J, Wanyiri J, Najafzadeh S, Ropchan J, Geha P, Huang Y, Potenza MN, Neumeister A, Carson RE, Malison RT. Reductions in brain 5-HT_{1B} receptor availability in primarily cocaine-dependent humans. *Biological Psychiatry* 2014, 76:816-22.
27. Smith JA, Patil DL, Daniels OT, Ding YS, **Gallezot JD**, Henry S, Kim KH, Kshirsagar S, Martin WJ, Obedencio GP, Stangeland E, Tsuruda PR, Williams W, Carson RE, Patil ST. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. *The International Journal Of Neuropsychopharmacology / Official Scientific Journal Of The Collegium Internationale Neuropsychopharmacologicum (CINP)* 2014, 18.
28. **Gallezot JD**, Kloczynski T, Weinzimmer D, Labaree D, Zheng MQ, Lim K, Rabiner EA, Ridler K, Pittman B, Huang Y, Carson RE, Morris ED, Cosgrove KP. Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(¹¹C)PHNO vs [(¹¹C)raclopride PET. *Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology* 2014, 39:866-74.
29. Castellan Baldan L, Williams KA, **Gallezot JD**, Pogorelov V, Rapanelli M, Crowley M, Anderson GM, Loring E, Gorczyca R, Billingslea E, Wasyluk S, Panza KE, Ercan-Sencicek AG, Krusong K, Leventhal BL, Ohtsu H, Bloch MH, Hughes ZA, Krystal JH, Mayes L, de Araujo I, Ding YS, State MW, Pittenger C. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. *Neuron* 2014, 81:77-90.
30. **Gallezot JD**, Zheng MQ, Lim K, Lin SF, Labaree D, Matuskey D, Huang Y, Ding YS, Carson RE, Malison RT. Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2014, 55:960-6.
31. **Gallezot JD**, Esterlis I, Bois F, Zheng MQ, Lin SF, Kloczynski T, Krystal JH, Huang Y, Sabri O, Carson RE, Cosgrove KP. Evaluation of the sensitivity of the novel $\alpha 4\beta 2^*$ nicotinic acetylcholine receptor

- PET radioligand 18F-(-)-NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys. *Synapse* (New York, N.Y.) 2014, 68:556-64.
32. Matuskey D, **Gallezot JD**, Pittman B, Williams W, Wanyiri J, Gaiser E, Lee DE, Hannestad J, Lim K, Zheng MQ, Lin SF, Labaree D, Potenza MN, Carson RE, Malison RT, Ding YS. Dopamine D₃ receptor alterations in cocaine-dependent humans imaged with [¹¹C](+)PHNO. *Drug And Alcohol Dependence* 2014, 139:100-5.
 33. Xia Y, Zheng MQ, Holden D, Lin SF, Kapinos M, Ropchan J, **Gallezot JD**, Huang Y, Carson RE. Measurement of Bmax and Kd with the glycine transporter 1 radiotracer ¹⁸F-MK6577 using a novel multi-infusion paradigm. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2015, 35:2001-9.
 34. Lin SF, Labaree D, Chen MK, Holden D, **Gallezot JD**, Kapinos M, Teng JK, Najafzadeh S, Plisson C, Rabiner EA, Gunn RN, Carson RE, Huang Y. Further evaluation of [¹¹C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. *Synapse* (New York, N.Y.) 2015, 69:86-95.
 35. Saricicek A, Chen J, Planeta B, Ruf B, Subramanyam K, Maloney K, Matuskey D, Labaree D, Deserno L, Neumeister A, Krystal JH, **Gallezot JD**, Huang Y, Carson RE, Bhagwagar Z. Test-retest reliability of the novel 5-HT_{1B} receptor PET radioligand [¹¹C]P943. *European Journal Of Nuclear Medicine And Molecular Imaging* 2015, 42:468-77.
 36. Hwang JJ, Yeckel CW, **Gallezot JD**, Aguiar RB, Ersahin D, Gao H, Kapinos M, Nabulsi N, Huang Y, Cheng D, Carson RE, Sherwin R, Ding YS. Imaging human brown adipose tissue under room temperature conditions with (11)C-MRB, a selective norepinephrine transporter PET ligand. *Metabolism: Clinical And Experimental* 2015, 64:747-55.
 37. Matuskey D, Gaiser EC, **Gallezot JD**, Angarita GA, Pittman B, Nabulsi N, Ropchan J, MacLeod P, Cosgrove KP, Ding YS, Potenza MN, Carson RE, Malison RT. A preliminary study of dopamine D_{2/3} receptor availability and social status in healthy and cocaine dependent humans imaged with [(11)C](+)PHNO. *Drug And Alcohol Dependence* 2015, 154:167-73.
 38. Bois F, **Gallezot JD**, Zheng MQ, Lin SF, Esterlis I, Cosgrove KP, Carson RE, Huang Y. Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine [(18)F]-(-)-NCFHEB as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. *Nuclear Medicine And Biology* 2015, 42:570-7.
 39. Park E, **Gallezot JD**, Delgadillo A, Liu S, Planeta B, Lin SF, O'Connor KC, Lim K, Lee JY, Chastre A, Chen MK, Seneca N, Leppert D, Huang Y, Carson RE, Pelletier D. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. *European Journal Of Nuclear Medicine And Molecular Imaging* 2015, 42:1081-92.
 40. Sandiego CM, **Gallezot JD**, Lim K, Ropchan J, Lin SF, Gao H, Morris ED, Cosgrove KP. Reference region modeling approaches for amphetamine challenge studies with [¹¹C]FLB 457 and PET. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2015, 35:623-9.
 41. Yoder KK, Territo PR, Hutchins GD, Hannestad J, Morris ED, **Gallezot JD**, Normandin MD, Cosgrove KP. Comparison of standardized uptake values with volume of distribution for quantitation of [(11)C]PBR28 brain uptake. *Nuclear Medicine And Biology* 2015, 42:305-8.
 42. Park E, Sullivan JM, Planeta B, **Gallezot JD**, Lim K, Lin SF, Ropchan J, McCarthy TJ, Ding YS, Morris ED, Williams WA, Huang Y, Carson RE. Test-retest reproducibility of the metabotropic glutamate

- receptor 5 ligand [¹⁸F]FPEB with bolus plus constant infusion in humans. *European Journal Of Nuclear Medicine And Molecular Imaging* 2015, 42:1530-41.
43. Sandiego CM, **Gallezot JD**, Pittman B, Nabulsi N, Lim K, Lin SF, Matuskey D, Lee JY, O'Connor KC, Huang Y, Carson RE, Hannestad J, Cosgrove KP. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. *Proceedings Of The National Academy Of Sciences Of The United States Of America* 2015, 112:12468-73.
44. Gaiser EC, **Gallezot JD**, Worhunsy PD, Jastreboff AM, Pittman B, Kantrovitz L, Angarita GA, Cosgrove KP, Potenza MN, Malison RT, Carson RE, Matuskey D. Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [¹¹C](+)-PHNO. *Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology* 2016, 41:3042-3050.
45. Pittenger C, Adams TG, **Gallezot JD**, Crowley MJ, Nabulsi N, James Ropchan, Gao H, Kichuk SA, Simpson R, Billingslea E, Hannestad J, Bloch M, Mayes L, Bhagwagar Z, Carson RE. OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. *Journal Of Affective Disorders* 2016, 196:87-96.
46. Yu Y, Chan C, Ma T, Liu Y, **Gallezot JD**, Naganawa M, Kelada OJ, Germino M, Sinusas AJ, Carson RE, Liu C. Event-by-Event Continuous Respiratory Motion Correction for Dynamic PET Imaging. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2016, 57:1084-90.
47. Matuskey D, Worhunsy P, Correa E, Pittman B, **Gallezot JD**, Nabulsi N, Ropchan J, Sreeram V, Gudepu R, Gaiser E, Cosgrove K, Ding YS, Potenza MN, Huang Y, Malison RT, Carson RE. Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)-PHNO in healthy volunteers. *NeuroImage* 2016, 130:241-247.
48. Wu J, Lin SF, **Gallezot JD**, Chan C, Prasad R, Thorn S, Stacy MR, Huang H, Zonouz TH, Liu YH, Lampert RJ, Carson RE, Sinusas AJ, Liu C. Quantitative Analysis of Dynamic 123I-mIBG SPECT Imaging Data in Healthy Humans with a Population-Based Metabolite Correction Method. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2016, 57:1226-32.
49. Wang A, Huen SC, Luan HH, Yu S, Zhang C, **Gallezot JD**, Booth CJ, Medzhitov R. Opposing Effects of Fasting Metabolism on Tissue Tolerance in Bacterial and Viral Inflammation. *Cell* 2016, 166:1512-1525.e12.
50. Hillmer AT, Esterlis I, **Gallezot JD**, Bois F, Zheng MQ, Nabulsi N, Lin SF, Papke RL, Huang Y, Sabri O, Carson RE, Cosgrove KP. Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. *NeuroImage* 2016, 141:71-80.
51. Sawant-Basak A, Chen L, Shaffer CL, Palumbo D, Schmidt A, Tseng E, Spracklin DK, **Gallezot JD**, Labaree D, Nabulsi N, Huang Y, Carson RE, McCarthy T. Quantitative projection of human brain penetration of the H3 antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. *Xenobiotica; The Fate Of Foreign Compounds In Biological Systems* 2017, 47:119-126.
52. DeLorenzo C, **Gallezot JD**, Gardus J, Yang J, Planeta B, Nabulsi N, Ogden RT, Labaree DC, Huang YH, Mann JJ, Gasparini F, Lin X, Javitch JA, Parsey RV, Carson RE, Esterlis I. In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [¹¹C]ABP688 and [¹⁸F]FPEB. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2017, 37:2716-2727.

53. **Gallezot JD**, Planeta B, Nabulsi N, Palumbo D, Li X, Liu J, Rowinski C, Chidsey K, Labaree D, Ropchan J, Lin SF, Sawant-Basak A, McCarthy TJ, Schmidt AW, Huang Y, Carson RE. Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2017, 37:1095-1107.
54. Germino M, **Gallezot JD**, Yan J, Carson RE. Direct reconstruction of parametric images for brain PET with event-by-event motion correction: evaluation in two tracers across count levels. *Physics In Medicine And Biology* 2017, 62:5344-5364.
55. Worhunsky PD, Matuskey D, **Gallezot JD**, Gaiser EC, Nabulsi N, Angarita GA, Calhoun VD, Malison RT, Potenza MN, Carson RE. Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder. *NeuroImage* 2017, 148:343-351.
56. Wu J, **Gallezot JD**, Lu Y, Ye Q, Liu H, Esserman DA, Kyriakides TC, Thorn S, Hashemi Zonouz T, Liu YH, Lampert R, Sinusas AJ, Carson RE, Liu C. Simplified Quantification and Acquisition Protocol for 123I-MIBG Dynamic SPECT. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2018, 59:1574-1580.
57. Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, **Gallezot JD**, Henry S, Hannestad J, Huang Y, Carson RE. Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2018, 38:2041-2052.
58. **Gallezot JD**, Nabulsi NB, Holden D, Lin SF, Labaree D, Ropchan J, Najafzadeh S, Donnelly DJ, Cao K, Bonacorsi S, Seiders J, Roppe J, Hayes W, Huang Y, Du S, Carson RE. Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand 11C-BMT-136088 for Lung Imaging in Rhesus Monkeys. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2018, 59:327-333.
59. Lattin CR, Emerson MA, **Gallezot JD**, Mulnix T, Brown JE, Carson RE. A 3D-printed modular device for imaging the brain of small birds. *Journal Of Neuroscience Methods* 2018, 293:183-190.
60. Belfort-DeAguiar RD, **Gallezot JD**, Hwang JJ, Elshafie A, Yeckel CW, Chan O, Carson RE, Ding YS, Sherwin RS. Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia. *The Journal Of Clinical Endocrinology And Metabolism* 2018, 103:2244-2252.
61. Radhakrishnan R, Nabulsi N, Gaiser E, **Gallezot JD**, Henry S, Planeta B, Lin SF, Ropchan J, Williams W, Morris E, D'Souza DC, Huang Y, Carson RE, Matuskey D. Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2018, 59:1445-1450.
62. Kelada OJ, Decker RH, Nath SK, Johung KL, Zheng MQ, Huang Y, **Gallezot JD**, Liu C, Carson RE, Oelfke U, Carlson DJ. High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. *International Journal Of Radiation Oncology, Biology, Physics* 2018, 102:174-183.
63. Ye Q, Wu J, Lu Y, Naganawa M, **Gallezot JD**, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. *Physics In Medicine And Biology* 2018, 63:175015.

64. Naganawa M, **Gallezot JD**, Rossano S, Carson RE. Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy. *Bulletin Of Mathematical Biology* 2019, 81:3508-3541.
65. Lu Y, **Gallezot JD**, Naganawa M, Ren S, Fontaine K, Wu J, Onofrey JA, Toyonaga T, Boutagy NE, Mulnix T, Panin VY, Casey ME, Carson RE, Liu C. Data-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PET. *Physics In Medicine And Biology* 2019, 64:065002.
66. **Gallezot JD**, Nabulsi NB, Henry S, Pracitto R, Planeta B, Ropchan J, Lin SF, Labaree D, Kapinos M, Shiralí A, Lara-Jaime T, Gao H, Matuskey D, Walzer M, Marek G, Bellaire S, Yuan N, Carson RE, Huang Y. Imaging the Enzyme 11 β -Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer 11C-AS2471907 in Human Brain. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2019, 60:1140-1146.
67. Toyonaga T, Smith LM, Finnema SJ, **Gallezot JD**, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y, Strittmatter SM, Carson RE. In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2019, 60:1780-1786.
68. Tuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A, Collste K, **Gallezot JD**, Hillmer A, Huang Y, Höglund CO, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego CM, Stenkrona P, Rinne J, Matuskey D, Cervenka S. Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study. *European Journal Of Nuclear Medicine And Molecular Imaging* 2019, 46:2329-2338.
69. Shi L, Lu Y, Wu J, **Gallezot JD**, Boutagy N, Thorn S, Sinusas AJ, Carson RE, Liu C. Direct List Mode Parametric Reconstruction for Dynamic Cardiac SPECT. *IEEE Transactions On Medical Imaging* 2020, 39:119-128.
70. Bini J, Sanchez-Rangel E, **Gallezot JD**, Naganawa M, Nabulsi NB, Lim K, Nahafzadeh S, Shiralí A, Ropchan J, Matuskey D, Huang H, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. *Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine* 2020, 61:570-576.
71. Sanchez-Rangel E, **Gallezot JD**, Yeckel CW, Lam W, Belfort-DeAguiar R, Chen MK, Carson RE, Sherwin R, Hwang JJ. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB. *International Journal Of Obesity (2005)* 2020, 44:964-967.
72. Holmes SE, **Gallezot JD**, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, Krystal JH, Javitch JA, DeLorenzo C, Carson RE, Esterlis I. Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET. *Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism* 2020, 40:2254-2264.
73. Radhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, **Gallezot JD**, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT₆ and 5-HT_{2A} receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. *Psychiatry Research. Neuroimaging* 2020, 295:111007.
74. Lu Y, Naganawa M, Toyonaga T, **Gallezot JD**, Fontaine K, Ren S, Revilla EM, Mulnix T, Carson RE. Data-Driven Motion Detection and Event-by-Event Correction for Brain PET: Comparison with

- Vicra. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2020, 61:1397-1403.
75. Bini J, Bhatt S, Hillmer AT, **Gallezot JD**, Nabulsi N, Pracitto R, Labaree D, Kapinos M, Ropchan J, Matuskey D, Sherwin RS, Jastreboff AM, Carson RE, Cosgrove K, Huang Y. Body Mass Index and Age Effects on Brain 11 β -Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. Molecular Imaging And Biology : MIB : The Official Publication Of The Academy Of Molecular Imaging 2020, 22:1124-1131.
76. Smart K, **Gallezot JD**, Nabulsi N, Labaree D, Zheng MQ, Huang Y, Carson RE, Hillmer AT, Worhunsky PD. Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. NeuroImage 2020, 214:116762.
77. Wu J, Boutagy NE, Cai Z, Lin SF, Zheng MQ, Feher A, Stendahl JC, Kapinos M, **Gallezot JD**, Liu H, Mulnix T, Zhang W, Lindemann M, Teng JK, Miller EJ, Huang Y, Carson RE, Sinusas AJ, Liu C. Feasibility study of PET dynamic imaging of [18F]DHMT for quantification of reactive oxygen species in the myocardium of large animals. Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology 2020.
78. Finnema SJ, Toyonaga T, Detyniecki K, Chen MK, Dias M, Wang Q, Lin SF, Naganawa M, **Gallezot JD**, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11 C]UCB-J positron emission tomography study. Epilepsia 2020, 61:2183-2193.
79. Tran TT, **Gallezot JD**, Jilaveanu LB, Zito C, Turcu G, Lim K, Nabulsi N, Huang H, Huttner A, Kluger HM, Chiang VL, Carson R. [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging 2020, 19:1536012120968669.
80. Naganawa M, **Gallezot JD**, Shah V, Mulnix T, Young C, Dias M, Chen MK, Smith AM, Carson RE. Assessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PET. EJNMMI Physics 2020, 7:67.
81. Naganawa M, **Gallezot JD**, Finnema S, Matuskey D, Mecca AP, Nabulsi NB, Labaree D, Ropchan J, Malison RT, D'Souza DC, Esterlis I, Detyniecki K, van Dyck CH, Huang Y, Carson RE. Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2021, 62:418-421.
82. Worhunsky PD, Angarita GA, Zhai ZW, Matuskey D, **Gallezot JD**, Malison RT, Carson RE, Potenza MN. Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2021, 46:316-324.
83. Chen MK, Mecca AP, Naganawa M, **Gallezot JD**, Toyonaga T, Mondal J, Finnema SJ, Lin SF, O'Dell RS, McDonald JW, Michalak HR, Vander Wyk B, Nabulsi NB, Huang Y, Arnsten AF, van Dyck CH, Carson RE. Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism 2021, 271678X211004312.